Clinical Trial Detail

NCT ID NCT02168777
Title Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bayer
Indications

lung non-small cell carcinoma

colorectal cancer

breast cancer

Advanced Solid Tumor

Therapies

Refametinib + Regorafenib

Refametinib

Age Groups: adult

Additional content available in CKB BOOST